Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2784544 · 3 trials · 8 indications
| Arm | Type | Description |
|---|---|---|
| 120 mg LY2784544 | EXPERIMENTAL | 120 milligram (mg) administered orally once daily for 6 cycles (168 days) |
| Part A: LY2784544 Dosing Regimen A | EXPERIMENTAL | LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days. |
| Part A: LY2784544 Dosing Regimen B | EXPERIMENTAL | LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days. |
| Part B: LY2784544 Dosing Regimen A | EXPERIMENTAL | LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days. |
| Part B: LY2784544 Dosing Regimen B | EXPERIMENTAL | LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days. |
| LY2784544 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 120 mg LY2784544 | DRUG | Administered orally |
| LY2784544 | DRUG | LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days. |
Inclusion Criteria: * Have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) as defined by the World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (Swerdlow et al. 2008) and meet the following additional subtype specific cr...
LY2784544 is an investigational small molecule being studied for myeloproliferative neoplasms and related hematologic cancers, including polycythemia vera, essential thrombocythemia, and myelofibrosis. It is being developed by Eli Lilly and Company (ticker: LLY) and has been tested in Phase 1 and Phase 2 clinical trials in adults with these conditions.
LY2784544 is being developed by Eli Lilly and Company, which trades under the ticker LLY. The drug is an investigational small molecule in Lilly's oncology pipeline, studied in myeloproliferative neoplasms and other hematologic conditions.
LY2784544 has been studied in Phase 1 and Phase 2 clinical trials. One Phase 2 trial, NCT01594723, is active but not recruiting, while two Phase 1 trials, NCT01520220 and NCT01134120, are completed. The drug remains investigational and is not approved for commercial use.
LY2784544 has been evaluated in three registered trials: NCT01594723, a Phase 2 study in hematologic neoplasms that is active but not recruiting; NCT01520220, a completed Phase 1 alternative dosing study in myeloproliferative neoplasms; and NCT01134120, a completed Phase 1 study in myeloproliferative disorders. These trials enrolled adults across multiple countries.